A phase I study evaluating abemaciclib, as monotherapy or with continued endocrine therapy, in 47 women with ABC who had received a median of seven (range 2‒16) prior systemic therapies showed partial responses in 4/11 patients (36%) with HR+/HER2+ ABC [81]. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.